United-Guardian reports Q1 2026 financials: sales up 16%, net income up 46%, driven by pharmaceuticals and cosmetic ingredients.
Quiver AI Summary
United-Guardian, Inc. reported strong financial results for the first quarter of 2026, with sales rising to $2,872,222 from $2,481,127 a year earlier, and net income increasing from $560,895 to $818,902. The growth was driven by a 24% increase in pharmaceutical sales, particularly for Renacidin, and a 21% rise in cosmetic ingredient sales, notably due to a 45% increase in purchases by Ashland Specialty Ingredients (ASI), which had previously seen lower purchases due to excess inventory. Additionally, the company benefited from settlement income related to a past disruption with a contract manufacturer. With renewed purchasing patterns from ASI, new distribution agreements, and a focus on expanding natural product lines, United-Guardian is optimistic about continued growth throughout 2026.
Potential Positives
- First quarter sales increased to $2,872,222 in 2026, up from $2,481,127 in 2025, indicating strong growth.
- Net income rose to $818,902 ($0.18 per share), compared to $560,895 ($0.12 per share) in the previous year, reflecting improved profitability.
- Pharmaceutical sales experienced a significant increase of 24%, driven by higher demand for Renacidin®, highlighting product success.
- Restoration of regular purchasing patterns from Ashland Specialty Ingredients (ASI) and new distribution agreements are expected to further boost sales, indicating positive future growth potential.
Potential Negatives
- Increased reliance on settlement income from the contract manufacturer of Renacidin suggests potential vulnerabilities in the supply chain or production capacity, which could impact future sales stability.
- Pharmaceutical sales increase was primarily driven by a single product, Renacidin, raising concerns about the lack of diversification in revenue sources.
- The acknowledgment of previous excess inventory issues with the largest distributor may indicate challenges in demand forecasting or inventory management that could affect future sales performance.
FAQ
What are the financial results for United-Guardian in Q1 2026?
United-Guardian reported Q1 2026 sales of $2,872,222 and net income of $818,902, an increase from Q1 2025.
How much did United-Guardian's net income increase?
Net income increased from $560,895 in Q1 2025 to $818,902 in Q1 2026.
What factors contributed to United-Guardian's sales growth in 2026?
Sales growth was driven by increased demand for pharmaceuticals and cosmetic ingredients, particularly Renacidin®.
What was the percentage increase in pharmaceutical sales?
Pharmaceutical sales rose by 24% in the first quarter of 2026 compared to the same period in 2025.
Who is the largest distributor for United-Guardian's cosmetic ingredients?
Ashland Specialty Ingredients (ASI) is the largest distributor, with purchases increasing by 45% in Q1 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$UG Hedge Fund Activity
We have seen 6 institutional investors add shares of $UG stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORTHERN TRUST CORP removed 19,271 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $118,709
- NEUBERGER BERMAN GROUP LLC removed 10,832 shares (-51.1%) from their portfolio in Q4 2025, for an estimated $66,725
- RODGERS BROTHERS INC. removed 8,416 shares (-10.2%) from their portfolio in Q4 2025, for an estimated $51,842
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 7,013 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $43,200
- DIMENSIONAL FUND ADVISORS LP removed 6,407 shares (-8.5%) from their portfolio in Q1 2026, for an estimated $42,926
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 4,559 shares (+45.5%) to their portfolio in Q4 2025, for an estimated $28,083
- GAMCO INVESTORS, INC. ET AL added 3,000 shares (+1.9%) to their portfolio in Q4 2025, for an estimated $18,480
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Full Release
HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).
Donna Vigilante, President of United-Guardian, stated, “I am happy to report that sales and earnings increased in the first quarter of 2026 compared with the first quarter of 2025. Our financial performance was primarily driven by increased sales of both our pharmaceuticals and cosmetic ingredients. Pharmaceutical sales rose by 24% in the first quarter of 2026, driven primarily by increased demand for Renacidin ® , our most important pharmaceutical product. Sales of our cosmetic ingredients increased by 21%, with the increase primarily attributable to an increase in purchases by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). ASI’s purchases increased by 45% in the first quarter of 2026 compared with the first quarter of 2025. The lower purchases by ASI in 2025 were primarily the result of ASI carrying excess inventory, which suppressed its purchase levels. This excess inventory has now been worked off, and they have resumed regular purchase levels.”
“In addition to the increase in sales, our income for the quarter was also supplemented by settlement income we recognized from the contract manufacturer (“CM”) of Renacidin in connection with an unexpected shutdown at the CM’s facility in late 2023, which resulted in lost Renacidin sales.”
“With ASI resuming its regular purchasing pattern, new distribution agreements in place, increased emphasis on expanding our “natural” product lines, and our ongoing project to increase outreach and market penetration for Renacidin, we are optimistic that our sales will continue to increase in 2026.”
United-Guardian is a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
| Contact: |
Donna Vigilante
(631) 273-0900 [email protected] |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
|
FINANCIAL RESULTS FOR THE
THREE MONTHS ENDED MARCH 31, 2026 AND 2025 UNITED-GUARDIAN, INC. STATEMENTS OF INCOME (UNAUDITED) |
|||||||
| Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Net sales | $ | 2,872,222 | $ | 2,481,127 | |||
| Costs and expenses: | |||||||
| Cost of sales | 1,447,789 | 1,123,076 | |||||
| Operating expenses | 666,963 | 632,735 | |||||
| Research and development | 115,021 | 114,394 | |||||
| Total costs and expenses | 2,229,773 | 1,870,205 | |||||
| Income from operations | 642,449 | 610,922 | |||||
| Other income: | |||||||
| Investment income | 69,814 | 84,687 | |||||
| Net gain on marketable securities | 17,742 | 12,350 | |||||
| Settlement income | 303,133 | --- | |||||
| Total other income | 390,689 | 97,037 | |||||
| Income before provision for income taxes | 1,033,138 | 707,959 | |||||
| Provision for income taxes | 214,236 | 147,064 | |||||
| Net income | $ | 818,902 | $ | 560,895 | |||
| Earnings per common share (basic and diluted) | $ | 0.18 | $ | 0.12 | |||
| Weighted average shares (basic and diluted) | 4,594,319 | 4,594,319 | |||||